As of 08/05/2022
  Indus: 32,803 +76.65 +0.2%  
  Trans: 14,601 +122.31 +0.8%  
  Utils: 1,014 -7.66 -0.7%  
  Nasdaq: 12,658 -63.03 -0.5%  
  S&P 500: 4,145 -6.75 -0.2%  
YTD
-9.7%  
-11.4%  
 +3.4%  
-19.1%  
-13.0%  
  Targets    Overview: 07/28/2022  
  Up arrow33,300 or 31,400 by 08/15/2022
  Up arrow15,200 or 13,400 by 08/15/2022
  Up arrow1,040 or 975 by 08/15/2022
  Up arrow12,900 or 11,300 by 08/15/2022
  Up arrow4,200 or 3,900 by 08/15/2022
CPI (updated daily): Arrows on 7/15/22
As of 08/05/2022
  Indus: 32,803 +76.65 +0.2%  
  Trans: 14,601 +122.31 +0.8%  
  Utils: 1,014 -7.66 -0.7%  
  Nasdaq: 12,658 -63.03 -0.5%  
  S&P 500: 4,145 -6.75 -0.2%  
YTD
-9.7%  
-11.4%  
 +3.4%  
-19.1%  
-13.0%  
  Targets    Overview: 07/28/2022  
  Up arrow33,300 or 31,400 by 08/15/2022
  Up arrow15,200 or 13,400 by 08/15/2022
  Up arrow1,040 or 975 by 08/15/2022
  Up arrow12,900 or 11,300 by 08/15/2022
  Up arrow4,200 or 3,900 by 08/15/2022
CPI (updated daily): Arrows on 7/15/22

Bulkowski's Vivus Trade

This article discusses a trade in the biotech firm, Vivus.

 

Picture of Vivus (VVUS) on the daily scale.

The chart shows a trade I made in Vivus (VVUS), on the daily scale.

On Sept 9, 2009 the company "Announces positive results from two phase 3 studies; obese patients on Qnexa achieve average weight loss up to 14.7%" according to google. As the chart shows, the stock responded by gapped higher from 6.91 to 11.80, or 71%, at B.

Two days later, the CEO sold 200,000 shares. Smart move. The two blue As are an Adam & Adam double top chart pattern, suggesting the stock would drop, which it did.

At C, the company announced that they would sell 9 million shares. The stock dropped 5% after hours. Two days later, they set the price at 10.50 and completed the offering on the 23rd..

As the steady decline shows, anyone participating in the offering got hosed.

Price bottomed at 7.07, almost closing the gap at B. Five days later, I bought the stock and received a fill at 7.80. My notes for the trade say, "11/11/09: I believe this has retraced all it's going to so now is the time to buy. The stock has hit support setup by the bottom of the large gap and a prior peak in late July."

Vivus: The Sale

It took a while for the stock to move higher, but that was the general trend. Since I didn't expect to sell anytime soon, I ignored the stock until June 15 (that means I checked it daily but saw nothing of concern).

My trading notebook has the following entry on the sale. "Downward breakout from a symmetrical triangle with possible negative potential on FDA approval due to heart side effects. ONE analyst speculates that the FDA will turn down the drug due to insufficient evidence that it does NOT hurt the heart. Got a great fill considering it opened at 10.56."

I sold the stock the next day, June 16, and received a fill at 10.71. I made 37% on the trade. The reason I sold the stock is because I got burned earlier in the year on Medivation, and didn't want to ride this stock from a profit to a loss, as I did that one.

Fortunately, I was lucky enough to sell the stock when I did. A month after I sold, the FDA rejected the weight-loss drug on safety concerns. The exchange halted trading and after hours the stock was down 57%. When it opened again, the stock closed 55% lower, eventually sinking to a low of 4.69 before recovering.

-- Thomas Bulkowski

Top of page More

See Also

 

Support this site! Clicking any of the books (below) takes you to Amazon.com If you buy ANYTHING while there, they pay for the referral.
Legal notices: "As an Amazon Associate I earn from qualifying purchases." Paid links).

My novels:  Bedroom to Boardroom bookBedroom to Boardroom book Remember Me bookRemember Me book Bumper's Story book Head's Law book

Chart Patterns: After the Buy Getting Started in Chart Patterns 2nd edition book Trading Basics book Fundamental Analysis and Position Trading book Swing and Day Trading book Encyclopedia of chart patterns book Encyclopedia of Chart Patterns 3rd Edition book Trading classic chart patterns book


Copyright © 2005-2022 by Thomas N. Bulkowski. All rights reserved.
Disclaimer: You alone are responsible for your investment decisions. See Privacy/Disclaimer for more information.
Some pattern names are registered trademarks of their respective owners.
Home Advertise Contact Donate Links Privacy/Disclaimer

The superfluous is very necessary. -- VoltaireSmiley